LYRA · Lyra Therapeutics, Inc.
$0.50
+0.00 (+0.00%)
At close · Jul 28
Going-concern doubt
— flagged Mar 31, 2026
Substantial doubt about the company's ability to continue as a going concern.
“our recurring losses from operations raise substantial doubt regarding our ability to continue as a going concern”View the 10-K filed Mar 31, 2026
Market Cap
$887,441
Shares
1.77M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| John E. Bishop | CTO | $1,030,415 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Harlan Waksal | Chairman | $5,027,375 |
| Maria Palasis | CEO | $1,735,751 |
| Richard Nieman | Chief Medical Officer | $1,399,467 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Maria Palasis | CEO | $1,754,599 |
| R. Don Elsey | CFO | $829,442 |
| Jason Cavalier | CFO | $782,861 |
| Corinne Noyes | Senior VP of Commercial Strategy and Market Development | $653,334 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Maria Palasis | CEO | $4,301,741 |
| R. Don Elsey | CFO | $760,686 |
| Robert Richard | Senior Vice President of Technical Operations | $549,598 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Maria Palasis | CEO | $842,684 |
| R. Don Elsey | CFO | $737,778 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Mr. Jason Cavalier | Chief Financial Officer | Terminated | 2026-01-12 |
| Dr. Maria Palasis | Chairman of the Board | Terminated | 2026-01-12 |
| Dr. Maria Palasis | Chief Executive Officer | Terminated | 2026-01-12 |